company background image
URGN

UroGen Pharma NasdaqGM:URGN Stock Report

Last Price

US$8.32

Market Cap

US$192.1m

7D

9.5%

1Y

-31.2%

Updated

29 Nov, 2022

Data

Company Financials +
URGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

URGN Stock Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

UroGen Pharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UroGen Pharma
Historical stock prices
Current Share PriceUS$8.32
52 Week HighUS$12.63
52 Week LowUS$4.85
Beta0.93
1 Month Change-30.44%
3 Month Change11.68%
1 Year Change-31.18%
3 Year Change-73.65%
5 Year Change-78.45%
Change since IPO-40.49%

Recent News & Updates

Recent updates

UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans

Mar 09
UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate

Nov 04
We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate

Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?

Jun 14
Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?

What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates

May 18
What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates

What Type Of Returns Would UroGen Pharma's(NASDAQ:URGN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would UroGen Pharma's(NASDAQ:URGN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth Carefully

Feb 17
We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth Carefully

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term

Jan 27
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term

How Much Of UroGen Pharma Ltd. (NASDAQ:URGN) Do Insiders Own?

Jan 06
How Much Of UroGen Pharma Ltd. (NASDAQ:URGN) Do Insiders Own?

President Elizabeth Barrett Just Bought 4.6% More Shares In UroGen Pharma Ltd. (NASDAQ:URGN)

Dec 16
President Elizabeth Barrett Just Bought 4.6% More Shares In UroGen Pharma Ltd. (NASDAQ:URGN)

UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years.

Dec 08
UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years.

Shareholder Returns

URGNUS BiotechsUS Market
7D9.5%-1.0%-0.9%
1Y-31.2%-15.2%-18.9%

Return vs Industry: URGN underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: URGN underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is URGN's price volatile compared to industry and market?
URGN volatility
URGN Average Weekly Movement10.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: URGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: URGN's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004195Liz Barretthttps://www.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

UroGen Pharma Ltd. Fundamentals Summary

How do UroGen Pharma's earnings and revenue compare to its market cap?
URGN fundamental statistics
Market CapUS$192.11m
Earnings (TTM)-US$109.37m
Revenue (TTM)US$62.44m

3.1x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
URGN income statement (TTM)
RevenueUS$62.44m
Cost of RevenueUS$6.98m
Gross ProfitUS$55.46m
Other ExpensesUS$164.83m
Earnings-US$109.37m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.74
Gross Margin88.82%
Net Profit Margin-175.16%
Debt/Equity Ratio-113.6%

How did URGN perform over the long term?

See historical performance and comparison